Close Menu
Michael A. Koren, MD

Associate Professor

Contact

MichaelKoren@creighton.edu
School of Medicine
Department of Medicine
Infectious Diseases Divisions
Infectious Diseases Fellowships

Michael A. Koren, MD

Associate Professor

Board Certifications: Internal Medicine and Infectious Disease
Areas of Interest: Antimicorbial Stewardship
Fellowship: Walter Reed National Military Medical Center
Residency: Madigan Army Medical Center
Medical School: Uniformed Services University of Health Sciences

Research Focus

Arboviruses
Respiratory Viruses

Department

Medicine

Position

Associate Professor

Articles

  • PubMed
    Koren MA, , Lin L, Eckels KH, De La Barrera R, Dussupt V, Donofrio G, Sondergaard EL, Mills KT, Robb ML, Lee C, Adedeji O, Keiser P, Curley J, Copeland N, Crowell T, Hutter J, Hamer M, Valencia-Ruiz A, Darden J, Peel S, Amare M, Mebrahtu T, Costanzo M, Krebs SJ, Gromowski G, Jarman RG, Thomas SJ, Michael NL, Modjarrad K. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomized, double-blind, placebo-controlled clinical trial. 2023
  • PubMed
    Lin L,, Koren MA, Paolino KM, Eckels KH, De La Barrera R, Friberg H, Currier JR, Gromowski GD, Aronson NE, Keiser PB, Sklar MJ, Sondergaard EL, Jasper LE, Endy TP, Jarman RG, Thomas SJ. Immunogenicity of a Live Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase I Randomized Clinical Trial 2021
  • PubMed
    Lima NS,, Moon D, Darko S, De La Barrera RA, Lin L, Koren MA, Jarman RG, Eckels KH, Thomas SJ, Michael NL, Modjarrad K, Douek DC, Trautmann L. Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine 2021
  • PubMed
    Lin L,, Koren M, Jarman RG, Eckels KH, Lepine E, McArthur MA, Currier JR, Friberg H, Moris P, Keiser PB, De La Barrera R, Vaughn DW, Paris RM, Thomas SJ, Schmidt AC. Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study 2020
  • PubMed
    Diaz C,, Koren M, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG, De La Barrera R, Lepine E, Febo I, Vaughn DW, Wilson TM, Paris RM, Schmidt AC, Thomas SJ. Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study 2020
  • PubMed
    Dussupt V,, Sankhala RS, Gromowski GD, Donofrio G, De La Barrera RA, Larocca RA, Zaky W, Mendez-Rivera L, Choe M, Davidson E, McCracken MK, Brien JD, Abbink P, Bai H, Bryan AL, Bias CH, Berry IM, Botero N, Cook T, Doria-Rose NA, Escuer AGI, Frimpong JA, Geretz A, Hernandez M, Hollidge BS, Jian N, Kabra K, Leggat DJ, Liu J, Pinto AK, Rutvisuttinunt W, Setliff I, Tran U, Townsley S, Doranz BJ, Rolland M, McDermott AB, Georgiev IS, Thomas R, Robb ML, Eckels KH, Barranco E, Koren M, Smith DR, Jarman RG, George SL, Stephenson KE, Barouch DH, Modjarrad K, Michael NL, Joyce MG, Krebs SJ. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor 2020

Presentations

  • 2021

Awards

  • Meritorious Service Medal
  • Army Achievement Medal
};